This Article Full Text Full Text (PDF) All Versions of this Article: 200512-1861OCv1 173/11/1194    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teeter, J. G. Articles by Riese, R. J. Search for Related Content PubMed PubMed Citation Articles by Teeter, J. G. Articles by Riese, R. J.

Dissociation of Lung Function Changes with Humoral Immunity during Inhaled Human Insulin Therapy

Pfizer Global Research and Development, New London, Connecticut

Correspondence and requests for reprints should be addressed to John G. Teeter, M.D., Pfizer Global Research and Development, 50 Pequot Avenue, M56025-A4223, New London, CT 06320. E-mail: john.g.teeter{at}pfizer.com

Rationale: Inhaled human insulin (INH; Exubera [human insulin (recombinant DNA origin) Inhalation Powder]) causes small changes in pulmonary function and increases in insulin antibodies compared with subcutaneous (SC) insulin.

Objectives: To investigate the relationship between changes in pulmonary function and insulin antibodies and acute effects of INH on lung function.

Methods: In a 24-wk multicenter study, 226 patients with type 1 diabetes were randomized to receive daily premeal INH or SC insulin for 12 wk (comparative phase), followed by SC insulin for 12 wk (washout phase).

Measurements: Spirometry tests were conducted and insulin antibody levels were measured throughout the study. Acute insulin-induced changes in lung function were calculated as the difference between FEV₁ before, and 10 and 60 min after, insulin.

Main Results: There was a temporal dissociation between pulmonary function changes and insulin antibody generation. Small treatment group differences in changes in FEV₁ from baseline, favoring SC insulin, were fully manifest by 2 wk of INH therapy, did not increase during the remainder of the comparative phase, and resolved within 2 wk of INH discontinuation. By contrast, insulin antibody levels remained low for the first 2 wk with INH, increased during Weeks 2 to 12, and gradually declined during washout. There was no evidence of acute insulin-induced alterations in lung function 10 and 60 min postinhalation.

Conclusion: The small lung function changes observed with INH therapy are not mediated by the humoral immune response, or associated with acute decrements in lung function immediately after insulin inhalation.

Key Words: Exubera • insulin antibodies • spirometry

This article has been cited by other articles:

				M. C. Liu, R. J. Riese, K. Van Gundy, P. Norwood, B. E. Sullivan, P. F. Schwartz, and J. G. Teeter Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes Eur. Respir. J., July 1, 2008; 32(1): 180 - 188. [Abstract] [Full Text] [PDF]

				D. M. Mannino and S. Braman The Epidemiology and Economics of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 502 - 506. [Abstract] [Full Text] [PDF]

				S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]

				R. A. Wise, J. G. Teeter, R. L. Jensen, R. D. England, P. F. Schwartz, D. R. Giles, R. C. Ahrens, N. R. MacIntyre, R. J. Riese, and R. O. Crapo Standardization of the Single-Breath Diffusing Capacity in a Multicenter Clinical Trial Chest, October 1, 2007; 132(4): 1191 - 1197. [Abstract] [Full Text] [PDF]

				P. Norwood, R. Dumas, W. Cefalu, J.-F. Yale, R. England, R. Riese, J. Teeter, and on behalf of Exubera Phase 3 Study Group Randomized Study to Characterize Glycemic Control and Short-Term Pulmonary Function in Patients with Type 1 Diabetes Receiving Inhaled Human Insulin (Exubera) J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2211 - 2214. [Abstract] [Full Text] [PDF]

				W. T. Cefalu Point: Pulmonary Inhalation of Insulin: Another "Brick in the Wall" Diabetes Care, February 1, 2007; 30(2): 439 - 441. [Full Text] [PDF]